KMT2A and acute lymphoblastic leukemia: In a xenograft model of MLL-AF4 ALL, the BCL-2 inhibitor ABT-199 synergized with conventional induction-type chemotherapy[35], suggesting that altered histone methylation may directly contribute to poor chemosensitivity in this subtype of ALL.